Altretamine

Altretamine
Clinical data
Trade names	Hexalen
Other names	2,4,6-Tris(dimethylamino)-1,3,5-triazine
AHFS/Drugs.com	Monograph
MedlinePlus	a601200
License data	US FDA: Altretamine;
Pregnancy; category	AU: D;
Routes of; administration	Oral (capsules)
ATC code	L01XX03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Protein binding	94%
Metabolism	Extensive liver
Metabolites	Pentamethylmelamine, tetramethylmelamine
Elimination half-life	4.7–10.2 hours
Identifiers
	IUPAC name N2,N2,N4,N4,N6,N6-Hexamethyl-1,3,5-triazine-2,4,6-triamine;
CAS Number	645-05-6 ;
PubChem CID	2123;
IUPHAR/BPS	7112;
DrugBank	DB00488 ;
ChemSpider	2038 ;
UNII	Q8BIH59O7H;
KEGG	D02841 ;
ChEBI	CHEBI:24564 ;
ChEMBL	ChEMBL1455 ;
CompTox Dashboard (EPA)	DTXSID4022579 ;
ECHA InfoCard	100.010.391
Chemical and physical data
Formula	C9H18N6
Molar mass	210.285 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c(nc(nc1N(C)C)N(C)C)N(C)C;
	InChI InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3 ; Key:UUVWYPNAQBNQJQ-UHFFFAOYSA-N ;
	(verify)

Altretamine (trade name Hexalen), also called hexamethylmelamine, is an antineoplastic agent. It was approved by the U.S. FDA in 1990.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.